Article

Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma

Department of Medical Oncology and Hematology, Humanitas Clinical Institute of Rozzano, Milan, Italy.
Cancer (Impact Factor: 4.89). 04/2008; 112(7):1555-61. DOI: 10.1002/cncr.23337
Source: PubMed

ABSTRACT

Pemetrexed-cisplatin chemotherapy is the standard of care in the first-line treatment of unresectable malignant pleural mesothelioma (MPM). Second-line cytotoxic therapy is considered for a growing group of patients, but the optimal treatment has not been defined to date. Gemcitabine and vinorelbine have shown activity in the first-line setting. The objective of this study was to evaluate the activity and toxicity of the gemcitabine-vinorelbine combination in pemetrexed-pretreated patients with MPM.
From January 2004 to September 2006, 30 consecutive patients who were pretreated with pemetrexed with or without a platinum-derivative were enrolled. Gemcitabine 1000 mg/m(2) and vinorelbine 25 mg/m(2) were administered intravenously on Days 1 and 8 every 3 weeks. Treatment was repeated for a maximum of 6 cycles or until progression or unacceptable toxicity.
A partial response was observed in 3 patients (10%; 95% confidence interval [CI], 2.1-26.5%), and 10 patients (33.3%; 95% CI, 17.3-52.8%) had stable disease after treatment. Overall, 13 patients (43.3%; 95% CI, 25.5-62.6%) achieved disease control. The median time to progression was 2.8 months (range, 0.6-12.1 months), and the median survival was 10.9 months (range, 0.8-25.3 months). Hematologic toxicity was acceptable, with grade 3 or 4 neutropenia occurring in 11% of patients and thrombocytopenia occurring in 4% of patients; no case of febrile neutropenia was observed. Nonhematologic toxicity generally was mild.
The gemcitabine and vinorelbine combination was moderately active and had an acceptable toxicity profile in pemetrexed-pretreated patients with MPM. The role of second-line treatment in MPM needs to be evaluated in prospective trials in large series of patients who are stratified according to previous treatment and prognostic factors.

Download full-text

Full-text

Available from: Federico Cappuzzo, Jan 15, 2015
  • Source
    • "Gemcitabine is a polar deoxycytidine analogue. It can inhibit both DNA synthesis and ribonucleotide reductase [1] [2] [3] [4] [5] [6]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Gemcitabine (GEM), acyclovir, and 5-fluorouracil are synthetic nucleoside analogues. These drugs function by inhibiting both RNA and DNA synthesizes. In this study, we investigated the inhibition effects of these drugs (gemcitabine hydrochloride, acyclovir, and 5-fluorouracil) on hPON1 enzyme activity from human serum in vitro conditions. IC50 values for gemcitabine hydrochloride, acyclovir, and 5-fluorouracil were determined to be 26.610 mM, 255.885 mM, and 564.334 mM, respectively. hPON1 enzyme was purified from human serum using ammonium sulphate precipitation, DEAE-Sephadex A-50 ion-exchange chromatography and Sephadex G-200 gel-filtration chromatography. It was purified approximately 231 fold with 34.2% yield. For purity determination of the enzyme SDS polyacrylamide gel electrophoresis was used and molecular mass was approximately determined 43 kDa by this method.
    Full-text · Article · May 2014 · The Open Biochemistry Journal
  • Source
    • "Another target of gemcitabine is the enzyme ribonucleotide reductase (Table 1). Gemcitabine and the vinca-derived vinorelbine, which have shown activity as the first-line setting, have been recently also investigated in association with the objective of evaluating their activity and toxicity in pemetrexed (a new generation antifolate)-pretreated hMPM patients: the combination was only moderately active showing an acceptable toxicity profile (Zucali et al., 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The incidence of human malignant pleural mesothelioma (hMPM) is still increasing worldwide. hMPM prognosis is poor even if the median survival time has been slightly improved after the introduction of the up-to-date chemotherapy. Nevertheless, large phase II/III trials support the combination of platinum derivatives and pemetrexed or raltitrexed, as preferred first-line schedule. Better understanding of the molecular machinery of hMPM will lead to the design and synthesis of novel compounds targeted against pathways identified as crucial for hMPM cell proliferation and spreading. Among them, several receptors tyrosine kinase show altered activity in subsets of hMPM. This observation suggests that these kinases might represent novel therapeutic targets in this chemotherapy-resistant disease. Over these foundations, several promising studies are ongoing at preclinical level and novel molecules are currently under evaluation as well. Yet, established tumour cell lines, used for decades to investigate the efficacy of anticancer agents, although still the main source of drug efficacy studies, after long-term cultures tend to biologically diverge from the original tumour, limiting the predictive potential of in vivo efficacy. Cancer stem cells (CSCs), a subpopulation of malignant cells capable of self-renewal and multilineage differentiation, are believed to play an essential role in cancer initiation, growth, metastasization and relapse, being responsible of chemo- and radiotherapy refractoriness. According to the current carcinogenesis theory, CSCs represent the tumour-initiating cell (TIC) fraction, the only clonogenic subpopulation able to originate a tumour mass. Consequently, the recently described isolation of TICs from hMPM, the proposed main pharmacological target for novel antitumoural drugs, may contribute to better dissect the biology and multidrug resistance pathways controlling hMPM growth.
    Full-text · Article · Jan 2012 · British Journal of Pharmacology
  • Source
    • "Some promising activity was noted with pemetrexed alone[54], and a combination of cisplatin, irinotecan and mitomycine[52]. In a phase III study, patients with progressive disease were randomised to best supportive care (BSC) or second line pemetrexed single agent[56]. Time to progression was significantly longer in the pemetrexed arm but there was no improvement in overall survival. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This review addresses the management of MPM. In an introductory section, the etiology, epidemiology, presentation, diagnosis and staging of MPM will be reviewed. The evidence was collected by a systematic analysis of the literature (2000-2009) using the databases Medline (National Library of Medicine, USA), Embase (Elsevier, Netherlands), Cochrane Library (Great Britain), National Guideline Clearinghouse (USA), HTA Database (International Network of Agencies for Health Technology Assessment - INAHTA), NIH database (USA), International Pleural Mesothelioma Program - WHOLIS (WHO Database) with the following keywords and filters: pleura, cancer, mesothelioma, guidelines, treatment, surgery, chemotherapy, radiotherapy, palliation, supportive care, pleurodesis, review.
    Preview · Article · May 2010 · Critical reviews in oncology/hematology
Show more